secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tonix Pharmaceuticals Holding Corp. (TNXP)
CIK:        0001430306
Form:       8-K
Filed at:   2026-05-01T23:59:59+00:00
Accession:  0001999371-26-009744
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Tonix reports preliminary Q1 net loss $40.8M, cash $185.5M, revenue $6.9M
-------------------------------------------------------------------------

- Net loss for Q1 2026 was ~$40.8M, up from $16.8M in Q1 2025; revenue rose to $6.9M from $2.4M, led by TONMYA ($3.7M).
- Cash and equivalents at March 31, 2026: $185.5M; common shares outstanding as of April 30, 2026: 15,540,801.
- Net cash used in operations was $40.2M in Q1 2026 vs $16.6M in Q1 2025; capex was $1.7M vs $6,000.
- Raised $17.4M net from equity offerings in Q2 2026; cash runway expected into Q2 2027.
- Preliminary results subject to revision; final Q1 2026 10-Q expected on or about May 11, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1430306/000199937126009744/0001999371-26-009744-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1430306/000199937126009744/tnxp-8k_050126.htm
  HTML page:      https://secwatch.observer/filing/0001999371-26-009744

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer